2024
-
Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery.
Clin Exp Immunol. 2024 Apr 20:uxae030. doi: 10.1093/cei/uxae030. Online ahead of print. PMID: 38642547
2023
-
Hornsby H, Nicols AR, Longet S, Liu C, Tomic A, Angyal A, Kronsteiner B, Tyerman JK, Tipton T, Zhang P, Gallis M, Supasa P, Selvaraj M, Abraham P, Neale I, Ali M, Barratt NA, Nell JM, Gustafsson L, Strickland S, Grouneva I, Rostron T, Moore SC, Hering LM, Dobson SL, Bibi S, Mongkolsapaya J, Lambe T, Wootton D, Hall V, Hopkins S, Dong T, Barnes E, Screaton G; PITCH Consortium; Richter A, Turtle L, Rowland-Jones SL, Carroll M, Duncan CJA, Klenerman P, Dunachie SJ, Payne RP, de Silva TI. Nat Commun. 2023 Aug 21;14(1):5065. doi: 10.1038/s41467-023-40592-4. PMID: 37604803
-
Neale I, Ali M, Kronsteiner B, Longet S, Abraham P, Deeks AS, Brown A, Moore SC, Stafford L, Dobson SL, Plowright M, Newman TAH, Wu MY; Crick COVID Immunity Pipeline; Carr EJ, Beale R, Otter AD, Hopkins S, Hall V, Tomic A, Payne RP, Barnes E, Richter A, Duncan CJA, Turtle L, de Silva TI, Carroll M, Lambe T, Klenerman P, Dunachie S; PITCH Consortium. mBio. 2023 Oct 31;14(5):e0121223. doi: 10.1128/mbio.01212-23. Epub 2023 Sep 1. PMID: 37655880
- Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery
Mohammad Ali, Stephanie Longet, Isabel Neale, Patpong Rongkard, Forhad Uddin Hassan Chowdhury, Jennifer Hill, Anthony Brown, Stephen Laidlaw, Tom Tipton, Ashraful Hoque, Nazia Hassan, Carl-Philipp Hackstein, Sandra Adele, Hossain Delowar Akther, Priyanka Abraham, Shrebash Paul, Md Matiur Rahman, Md Masum Alam, Shamima Parvin, Forhadul Hoque Mollah, Md Mozammel Hoque, Shona C Moore, Subrata K Biswas, Lance Turtle, Thushan I de Silva, Ane Ogbe, John Frater, Eleanor Barnes, Adriana Tomic, Miles W Carroll, Paul Klenerman, Barbara Kronsteiner, Fazle Rabbi Chowdhury, Susanna J Dunachie
medRxiv 2023.06.14.23291375; doi: https://doi.org/10.1101/2023.06.14.23291375
2022
- Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nat Commun. 2022 Mar 10;13(1):1251. doi: 10.1038/s41467-022-28898-1. PubMed PMID: 35273178; PubMed Central PMCID: PMC8913789.
-
COMBAT consortium. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell. 2022 Mar 3;185(5):916-938.e58. doi: 10.1016/j.cell.2022.01.012. Epub 2022 Jan 21. PubMed PMID: 35216673; PubMed Central PMCID: PMC8776501.
-
Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19. Lancet Digit Health. 2022 Oct;4(10):e705-e716. doi: 10.1016/S2589-7500(22)00132-7. Epub 2022 Aug 26.
-
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cell Mol Immunol. 2022 Feb;19(2):234-244. doi: 10.1038/s41423-021-00814-5. Epub 2022 Jan 7.
2021
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1.
- Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 Jun;27(6):1113. doi: 10.1038/s41591-021-01372-z. PubMed PMID: 33958800; PubMed Central PMCID: PMC8101331.
- Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Jun;27(6):1116. doi: 10.1038/s41591-021-01363-0. PubMed PMID: 34021278.
-
Systems Immunology: Revealing Influenza Immunological Imprint. Viruses. 2021 May 20;13(5). doi: 10.3390/v13050948. Review. PubMed PMID: 34065617; PubMed Central PMCID: PMC8160800.
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19. PubMed PMID: 33617777; PubMed Central PMCID: PMC7894131.
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 Feb;27(2):279-288. doi: 10.1038/s41591-020-01179-4. Epub 2020 Dec 17. PubMed PMID: 33335322.
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17. PubMed PMID: 33335323.
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1.
-
SIMON: Open-Source Knowledge Discovery Platform. Patterns (N Y). 2021 Jan 8;2(1):100178. doi: 10.1016/j.patter.2020.100178. eCollection 2021 Jan 8. PubMed PMID: 33511368; PubMed Central PMCID: PMC7815964.
2020
- Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine. Mol Syst Biol. 2020 Nov;16(11):e9888. doi: 10.15252/msb.20209888. PubMed PMID: 33210468; PubMed Central PMCID: PMC7674973.
2019
- The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system. Sci Data. 2019 Oct 21;6(1):214. doi: 10.1038/s41597-019-0213-4. PubMed PMID: 31636302; PubMed Central PMCID: PMC6803714.
- SIMON, an Automated Machine Learning System, Reveals Immune Signatures of Influenza Vaccine Responses. J Immunol. 2019 Aug 1;203(3):749-759. doi: 10.4049/jimmunol.1900033. Epub 2019 Jun 14. PubMed PMID: 31201239; PubMed Central PMCID: PMC6643048.
2018
- Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018 May;19(5):453-463. doi: 10.1038/s41590-018-0082-6. Epub 2018 Apr 9. PubMed PMID: 29632329.
2016
- Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. PLoS Pathog. 2016 Dec;12(12):e1006015. doi: 10.1371/journal.ppat.1006015. eCollection 2016 Dec. PubMed PMID: 27907183; PubMed Central PMCID: PMC5131914.
- Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection. J Exp Med. 2016 Aug 22;213(9):1835-50. doi: 10.1084/jem.20151899. Epub 2016 Aug 8. PubMed PMID: 27503073; PubMed Central PMCID: PMC4995080.
2014
- Cytomegalovirus m154 hinders CD48 cell-surface expression and promotes viral escape from host natural killer cell control. PLoS Pathog. 2014 Mar;10(3):e1004000. doi: 10.1371/journal.ppat.1004000. eCollection 2014 Mar. PubMed PMID: 24626474; PubMed Central PMCID: PMC3953435.
2013
-
Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1γ. Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16550-5. doi: 10.1073/pnas.1310215110. Epub 2013 Sep 19. PubMed PMID: 24052528; PubMed Central PMCID: PMC3799388.